Waqar Siddiqui, MD
Psychiatry · South Plainfield, NJNPI 1699840314
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.4%), speaking fees and education — rather than concentrated in one kind of arrangement. AbbVie accounts for 61.3% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $2,972 and has fallen 85.2% since, to $440 in 2025. Among psychiatry clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 261 payments — averaging $38.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Teva Pharmaceuticals USA, Inc.$838
- Alkermes, Inc.$700
- Otsuka America Pharmaceutical, Inc.$581
- Lundbeck LLC$425
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$302
- plus $1K from 12 others
Across 27 payments — averaging $6676.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$85K
- AbbVie$73K
- E.r. Squibb & Sons, L.L.C.$18K
- Biogen$4K
What the payments were for
- Speaking & faculty fees$4,87549%
- Food & beverage$5,01550%
- Education$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 70 | $6,097 |
| Teva Pharmaceuticals USA, Inc. | 39 | $838 |
| Alkermes, Inc. | 38 | $700 |
| Otsuka America Pharmaceutical, Inc. | 32 | $581 |
| Lundbeck LLC | 23 | $425 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $302 |
| Indivior Inc. | 8 | $208 |
| Axsome Therapeutics, Inc. | 5 | $191 |
| Johnson & Johnson | 8 | $172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $100 |
| E.r. Squibb & Sons, L.L.C. | 3 | $83 |
| Vanda Pharmaceuticals Inc. | 3 | $71 |
| Almatica Pharma LLC | 3 | $46 |
| Bausch Health US, LLC | 2 | $41 |
| Acadia Pharmaceuticals Inc | 2 | $39 |
| Insmed, Inc. | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,950 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 35 | $53,154 |
| Invega SustennaPaliperidone Palmitate | 12 | $27,891 |
| Aripiprazole | 163 | $15,770 |
| Oxcarbazepine | 101 | $6,106 |
| Quetiapine Fumarate | 234 | $4,632 |
| Paliperidone ErPaliperidone | 31 | $3,849 |
| Perphenazine | 32 | $3,267 |
| Alprazolam | 419 | $3,020 |
| Clonazepam | 279 | $2,649 |
| Buspirone Hcl | 138 | $2,498 |
| Olanzapine | 62 | $2,110 |
| Bupropion Hcl SrBupropion Hcl | 139 | $2,108 |
| Escitalopram Oxalate | 239 | $2,084 |
| Risperidone | 120 | $1,882 |
| Duloxetine Hcl | 117 | $1,856 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $6,097 | $53,15435 claims |
| Johnson & JohnsonInvega Sustenna | $172 | $27,89112 claims |
| Almatica Pharma LLCSertraline Hcl | $46 | $1,225191 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Other psychiatry in South Plainfield
- Marc CantillonLivingston$522K
- Robert BransfieldRed Bank$415K
- Erika ConcepcionLong Branch$354K
- Leon RosenbergCherry Hill$257K
- Lloyd AlceraMarlton$187K
- Gary SmallHackensack$170K
- Shankar SrinivasanParsippany$155K
- Matthew PiteraToms River$153K
- Boris BorodulinEast Brunswick$116K
- Anthony RostainCamden$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.